Solid Biosciences (SLDB)
Nasdaq Market Open
Solid Biosciences Inc. is a life sciences company developing genetic medicines for serious neuromuscular and cardiac disorders. Its pipeline is centred on gene therapy and related approaches designed to address diseases caused by inherited genetic defects. The company operates as a clinical-stage biotechnology business, meaning its value is closely tied to research progress, clinical trial results, regulatory outcomes, and its ability to finance development.
The company’s lead areas include Duchenne muscular dystrophy, Friedreich’s ataxia, and genetic heart conditions. Its programs include SGT-003 for Duchenne muscular dystrophy, SGT-212 for Friedreich’s ataxia, SGT-501 for catecholaminergic polymorphic ventricular tachycardia, and SGT-601 for TNNT2-mediated dilated cardiomyopathy. These candidates are intended to deliver functional genetic material or otherwise address the biological cause of disease, rather than only treating symptoms. Solid Biosciences also works on additional assets aimed at genetic cardiac and neuromuscular conditions.
Duchenne muscular dystrophy and the cardiac diseases targeted by Solid Biosciences are severe conditions with high unmet medical need, making them important areas for advanced therapies. At the same time, gene therapy development is technically complex and carries meaningful risk, including manufacturing challenges, safety considerations, trial design issues, and regulatory scrutiny. Solid Biosciences’ business is therefore distinctive for its focus on rare inherited disorders where successful treatment could be transformative, but where progress depends on careful execution across science, clinical development, and approval pathways.
Last updated
- Market Cap
- 674.38M
- P/E
- —
- P/FCF
- —
- P/S
- —
- Enterprise Value
- 377.28M
- Sector
- Health Care
- Industry
- Biological Products, Except Diagnostic Substances
- Address
- 500 RUTHERFORD AVENUE, CHARLESTOWN, MA, 02129
Duchenne Muscular Dystrophy Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 75+ Leading Players Wheeling the Therapeutics Landscape
Solid Biosciences Announces Duchenne Muscular Dystrophy Added to National Recommended Uniform Screening Panel by the U.S. Department of Health and Human Services
Solid Biosciences Receives FDA Rare Pediatric Disease Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich’s Ataxia
Solid Biosciences Announces Licensing Agreement with Andelyn Biosciences for the Use of Proprietary Next-Generation Capsid AAV-SLB101
Solid Biosciences to Participate at Upcoming Investor Conferences
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dilated Cardiomyopathy Market Witnesses Robust Growth During the Study Period (2020–2034) Amid Advancements in Cardiovascular Therapies | DelveInsight
Solid Biosciences to Participate at Upcoming Investor Conferences
Rocket Lab stock downgraded by Morgan Stanley due to revised growth outlook By Investing.com - Investing.com
Solid Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
FDA Expands Sarepta's (SRPT) DMD Gene Therapy Label
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Solid Biosciences Provides First Quarter 2024 Business Update and Financial Results
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Solid Biosciences (SLDB) Falls Despite FDA Rare Tag for DMD Drug
Solid Biosciences Receives Rare Pediatric Disease Designation from the FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003
Solid Biosciences Provides Fourth Quarter and Full-Year 2023 Business Update and Financial Results
Beat the Market Like Zacks: Walmart, Novo Nordisk, Procter & Gamble in Focus
REGENXBIO (RGNX) Soars 15% on Interim Data From DMD Study
- Market Cap
Market cap is the total value of a company's shares, calculated by multiplying the stock price by the number of shares outstanding.
- 674.38M
- Enterprise Value
Enterprise value is the total value of a company, including its market cap, debt, and cash.
- 377.28M
- P/E
P/E ratio compares a company's share price to its earnings per share.
- —
- P/B
P/B ratio compares a company's share price to its book value per share.
- 1.8
- P/S
P/S ratio compares a company's share price to its revenue per share.
- —
- EV / EBITDA
EV/EBITDA measures a company's value compared to its earnings before interest, taxes, depreciation, and amortization.
- -1.94
- EV / Sales
EV/Sales measures a company's value compared to its total revenue.
- —
- EPS
- -1.95
- Dividend Yield
Dividend yield shows how much a company pays in dividends each year compared to its share price.
- 0%
- P/FCF
Price-to-free-cash-flow ratio compares a company's share price to the cash it generates after expenses and investments.
- —
- P/CF
P/CF ratio compares a company's share price to the cash flow it generates from its operations.
- —
- Free Cash Flow
Free cash flow is the cash a company has left after covering operating costs and capital expenses.
- -172.86M
- ROE
ROE measures how effectively a company uses shareholders' equity to generate profit.
- -51.26%
- ROA
ROA measures how effectively a company uses its assets to generate profit.
- -45.35%
- Debt / Equity
Debt-to-equity ratio compares a company's total debt to its shareholders' equity.
- 0
- Current Ratio
Current ratio measures a company's ability to pay short-term debts using its short-term assets.
- 13.08
- Quick Ratio
Quick ratio measures a company's ability to pay short-term debts using cash and other easily available assets.
- 13.08
- Cash
Cash ratio measures a company's ability to cover short-term debts using only cash and cash equivalents.
- 9.81
- Avg Volume
Average volume shows the average number of shares traded over the last 30 trading days, helping indicate liquidity.
- 1.09M
- Fundamentals Snapshot Price
Fundamentals snapshot price is the stock price used when calculating the company's financial ratios and metrics.
- 6.85
Income Statement
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -57.31M | -49.4M | -48.06M | -41.69M | -40.05M |
| EBITDA | -56.91M | -48.94M | -47.68M | -41.31M | -39.65M |
| Net income | -56.74M | -49.79M | -45.78M | -39.48M | -39.28M |
| Basic EPS | -0.52 | -0.53 | -0.48 | -0.42 | -0.59 |
| Diluted EPS | -0.52 | -0.53 | -0.48 | -0.42 | -0.59 |
Balance Sheet
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Total assets | 422.89M | 232.54M | 273.91M | 308.29M | 343.9M |
| Total liabilities | 48.76M | 52.53M | 55.97M | 50M | 49.44M |
| Total equity | 374.13M | 180.01M | 217.95M | 258.29M | 294.46M |
| Cash & equivalents | 297.1M | 59.9M | 61.36M | 138.93M | 210.63M |
| Current assets | 396.15M | 204.23M | 244.85M | 278.64M | 313.41M |
| Current liabilities | 30.28M | 33.47M | 36.34M | 29.85M | 28.78M |
Cash Flow
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Operating cash flow | -47.23M | -53.56M | -33.47M | -37.41M | -31.85M |
| Investing cash flow | 44.76M | 47.01M | -45.27M | -32.73M | -27.46M |
| Financing cash flow | 239.03M | 5.14M | 1.18M | -1.6M | 189.73M |
| Change in cash | 236.56M | -1.4M | -77.57M | -71.75M | 130.42M |
| Kind | Filing | Date | Link |
|---|---|---|---|
| edgar index | 10-Q — Solid Biosciences Inc. | View Filing | |
| edgar index | SCHEDULE 13G/A — Solid Biosciences Inc. | View Filing | |
| edgar index | SCHEDULE 13G/A — Solid Biosciences Inc. | View Filing | |
| edgar index | DEF 14A — Solid Biosciences Inc. | View Filing | |
| edgar index | DEFA14A — Solid Biosciences Inc. | View Filing | |
| edgar index | ARS — Solid Biosciences Inc. | View Filing | |
| edgar index | 4 — Solid Biosciences Inc. | View Filing | |
| edgar index | 4 — Solid Biosciences Inc. | View Filing | |
| edgar index | 4 — Solid Biosciences Inc. | View Filing | |
| edgar index | 4 — Solid Biosciences Inc. | View Filing | |
| edgar index | 4 — Solid Biosciences Inc. | View Filing | |
| edgar index | 4 — Solid Biosciences Inc. | View Filing | |
| edgar index | 8-K — Solid Biosciences Inc. | View Filing | |
| edgar index | PRE 14A — Solid Biosciences Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 4 — Solid Biosciences Inc. | View Filing | |
| form 4 | Form 4 — SMITH IAN F | View Filing | |
| form 4 | Form 4 — SMITH IAN F | View Filing | |
| edgar index | EFFECT — Solid Biosciences Inc. | View Filing | |
| edgar index | EFFECT — Solid Biosciences Inc. | View Filing | |
| edgar index | CORRESP — Solid Biosciences Inc. | View Filing | |
| edgar index | CORRESP — Solid Biosciences Inc. | View Filing | |
| edgar index | UPLOAD — Solid Biosciences Inc. | View Filing | |
| edgar index | UPLOAD — Solid Biosciences Inc. | View Filing | |
| edgar index | 10-K — Solid Biosciences Inc. | View Filing | |
| edgar index | S-8 — Solid Biosciences Inc. | View Filing | |
| edgar index | S-3 — Solid Biosciences Inc. | View Filing | |
| edgar index | S-3 — Solid Biosciences Inc. | View Filing | |
| ten k section | 10-K — business | View Filing | |
| ten k section | 10-K — mda | View Filing | |
| ten k section | 10-K — risk_factors | View Filing | |
| edgar index | SCHEDULE 13D/A — Solid Biosciences Inc. | View Filing | |
| edgar index | 8-K — Solid Biosciences Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 4 — Solid Biosciences Inc. | View Filing | |
| edgar index | SCHEDULE 13D/A — Solid Biosciences Inc. | View Filing | |
| edgar index | SCHEDULE 13D/A — Solid Biosciences Inc. | View Filing | |
| edgar index | SCHEDULE 13D/A — Solid Biosciences Inc. | View Filing | |
| form 4 | Form 4 — EDELMAN JOSEPH | View Filing | |
| form 4 | Form 4 — PERCEPTIVE ADVISORS LLC | View Filing | |
| form 4 | Form 4 — PERCEPTIVE LIFE SCIENCES MASTER FUND LTD | View Filing | |
| edgar index | 8-K — Solid Biosciences Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 4 — Solid Biosciences Inc. | View Filing | |
| edgar index | 144 — Solid Biosciences Inc. | View Filing | |
| edgar index | 4 — Solid Biosciences Inc. | View Filing | |
| edgar index | 144 — Solid Biosciences Inc. | View Filing | |
| edgar index | 4 — Solid Biosciences Inc. | View Filing | |
| edgar index | 4 — Solid Biosciences Inc. | View Filing | |
| edgar index | 144 — Solid Biosciences Inc. | View Filing | |
| edgar index | 144 — Solid Biosciences Inc. | View Filing | |
| edgar index | 4 — Solid Biosciences Inc. | View Filing | |
| edgar index | 144 — Solid Biosciences Inc. | View Filing | |
| edgar index | 4 — Solid Biosciences Inc. | View Filing | |
| edgar index | 144 — Solid Biosciences Inc. | View Filing | |
| edgar index | 144 — Solid Biosciences Inc. | View Filing | |
| edgar index | 4 — Solid Biosciences Inc. | View Filing | |
| form 4 | Form 4 — Tan Kevin | View Filing | |
| form 4 | Form 4 — Brooks Gabriel | View Filing | |
| form 4 | Form 4 — Howton David T | View Filing | |
| form 4 | Form 4 — Herzich Paul | View Filing | |
| form 4 | Form 4 — Ganot Ilan | View Filing | |
| form 4 | Form 4 — Hanrahan Jessie | View Filing | |
| form 4 | Form 4 — Cumbo Alexander | View Filing | |
| edgar index | SCHEDULE 13G — Solid Biosciences Inc. | View Filing | |
| form 4 | Form 4 — Tan Kevin | View Filing | |
| form 4 | Form 4 — Tan Kevin | View Filing | |
| form 4 | Form 4 — Brooks Gabriel | View Filing | |
| form 4 | Form 4 — Brooks Gabriel | View Filing | |
| form 4 | Form 4 — Howton David T | View Filing | |
| form 4 | Form 4 — Howton David T | View Filing | |
| form 4 | Form 4 — Herzich Paul | View Filing | |
| form 4 | Form 4 — Herzich Paul | View Filing | |
| form 4 | Form 4 — Ganot Ilan | View Filing | |
| form 4 | Form 4 — Ganot Ilan | View Filing |